FDA Approval and Product Identity

On December 12, 2025, the U.S. FDA approved Lerochol (lerodalcibep-liga) 300mg/1.2mL subcutaneous injection by LIB Therapeutics, Inc. for use in conjunction with diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerochol is a recombinant fusion protein that binds to PCSK9 and inhibits the degradation of LDL receptors, offering a monthly dosing regimen that differentiates it from existing injectables. An auto-injector formulation was additionally approved on August 17, 2026, enhancing dosing convenience.

Clinical Evidence and Patient Value

The approval was based on results from the global phase 3 LIBerate program, including NCT04797247, NCT04806893, and NCT04797104, which were randomized placebo-controlled trials. In two trials involving adults with ASCVD or high-risk profiles, the placebo-adjusted LDL-C reduction at 52 weeks was -55% and -50%, respectively, while the HeFH trial showed a -59% reduction at 24 weeks. The total population across the three trials was 2,322 patients, all evaluated on stable lipid-lowering therapy, including maximum tolerated dose statins. This demonstrated both the durability of effect and the convenience of monthly dosing. However, the approved indication is LDL-C reduction, and it should be distinguished from cardiovascular outcome indications that directly prove reductions in myocardial infarction or stroke.

Competitive Landscape and Market Size

Standard treatment typically involves statins with ezetimibe, and if target LDL-C is not achieved, PCSK9 inhibitors are added. Direct competitors include Amgen (AMGN)'s Repatha (evolocumab), Regeneron Pharmaceuticals (REGN)'s Praluent (alirocumab), and Novartis (NVS)'s Leqvio (inclisiran), all targeting the PCSK9 pathway. In 2025, Repatha generated USD 3.016 billion in revenue, and Leqvio generated USD 1.198 billion, together forming a validated market of USD 4.214 billion. The competitive landscape intensified further in July 2026 with Merck & Co. (MRK)'s first oral PCSK9 inhibitor, Lipfendra (enlicitide), which received FDA approval, adding another dimension to dosing convenience.

Commercialization and Regulatory Expansion

As a non-listed biotech company, LIB Therapeutics' commercial performance of Lerochol is a key indicator of enterprise value and future fundraising. In the U.S., the drug was launched in 2026 with a direct-to-consumer cash price of USD 199 per month, aiming to lower access barriers for existing PCSK9 therapies. In Europe, EMA review is ongoing, and in China, a BLA was submitted to NMPA in June 2026 by Everest Medicines (1952.HK) and Hasten Biopharmaceuticals. In the short term, the key factors are prescription growth and insurance coverage speed, while mid-term success will depend on regulatory expansion in Europe and China.